How does Strattera (atomoxetine) work?

How Strattera (Atomoxetine) Works

Strattera works by selectively blocking the norepinephrine transporter, which increases norepinephrine levels in brain synapses, and uniquely in the prefrontal cortex where norepinephrine transporters also regulate dopamine, it increases both norepinephrine and dopamine concentrations. 1

Mechanism of Action

Primary Pharmacological Effect:

• Atomoxetine is classified as a selective norepinephrine reuptake inhibitor that binds to and blocks the presynaptic norepinephrine transporter 1, 2
• This blockade prevents norepinephrine from being taken back up into neurons, thereby increasing its concentration in the synaptic space 1

Unique Prefrontal Cortex Action:

• In the prefrontal cortex specifically, dopamine transporters are scarce, so norepinephrine transporters handle dopamine reuptake as well 1
• Consequently, atomoxetine increases both noradrenaline AND dopamine in prefrontal cortex synapses, which is the brain region responsible for attention, impulse control, and executive function 1
• This dual neurotransmitter effect in the prefrontal cortex distinguishes atomoxetine from pure norepinephrine reuptake inhibitors 3

Clinical Pharmacology Details

Selectivity Profile:

• Atomoxetine has high affinity and selectivity for norepinephrine transporters with minimal affinity for other neurotransmitter receptors or transporters 3, 4
• It does not significantly affect serotonin, dopamine (outside prefrontal cortex), or other neurotransmitter systems 3

Metabolism Considerations:

• Atomoxetine is primarily metabolized through the CYP2D6 enzymatic pathway 1, 2
• Approximately 7% of the population are poor CYP2D6 metabolizers, resulting in 10-fold higher drug exposure (AUC) and 5-fold higher peak concentrations 1, 5
• Co-administration with potent CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) substantially increases atomoxetine plasma levels and requires dosing adjustment 1, 2, 5

Pharmacokinetic Profile

Absorption and Distribution:

• Reaches maximum plasma concentration in 1-2 hours after oral administration 2, 5
• Can be taken with or without food (food decreases peak concentration by 9-37% but doesn't affect total absorption) 2
• Volume of distribution is 0.85 L/kg, indicating distribution into total body water 2, 5
• Approximately 98-99% protein bound, primarily to albumin 2, 5

Elimination:

• In extensive metabolizers: half-life is 5.2 hours with clearance of 0.35 L/hr/kg 2, 5
• In poor metabolizers: half-life is 21.6 hours with clearance of 0.03 L/hr/kg 2, 5
• Excreted primarily as metabolites in urine (>80%), with less than 3% excreted unchanged 2

Clinical Implications

Therapeutic Effects:

• The increased norepinephrine and dopamine in the prefrontal cortex strengthens top-down regulation of attention, working memory, and impulse control 1
• Effects persist throughout waking hours with once-daily morning dosing 6
• Unlike stimulants, atomoxetine has negligible abuse potential and is not a controlled substance in the US 1, 7, 3, 4

Key Safety Monitoring:

• All children and adolescents must be monitored closely for suicidal ideation, especially during the first months of treatment or dose changes, based on FDA analysis showing increased risk in 4 out of 1000 patients 1, 2
• Monitor for cardiovascular effects (modest increases in heart rate and blood pressure) 1, 2
• Watch for rare but serious liver injury 1, 2
• Common adverse effects include nausea, vomiting, decreased appetite, abdominal pain, and somnolence 1